Article Text

Download PDFPDF

Original research article
A zero coronary artery calcium score in patients with stable chest pain is associated with a good prognosis, despite risk of non-calcified plaques
  1. Xue Wang1,
  2. Elizabeth Phuong Vi Le1,
  3. Nikil K Rajani2,
  4. NJ Hudson-Peacock1,
  5. Holly Pavey3,
  6. Jason M Tarkin1,
  7. Judith Babar4,
  8. Michelle Claire Williams5,
  9. Deepa Gopalan4 and
  10. James H F Rudd1
  1. 1Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
  2. 2Department of Clinical Radiology, Imperial College Hospitals NHS Trust, St Mary's Hospital, London, UK
  3. 3Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK
  4. 4Department of Radiology, Addenbrooke's Hospital, Cambridge, UK
  5. 5Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK
  1. Correspondence to Dr James H F Rudd, Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; jhfr2{at}cam.ac.uk

Abstract

Objectives To estimate the prevalence of non-calcified coronary artery disease (CAD) in patients with suspected stable angina and a zero coronary artery calcification (CAC) score, and to assess the prognostic significance of a zero CAC in these symptomatic patients.

Methods In this prospective cohort study, consecutive patients with stable chest pain underwent CAC scoring ± CT coronary angiography (CTCA) as part of routine clinical care at a single tertiary centre over 7 years. Major adverse cardiac event (MACE) was defined as cardiac death, non-fatal myocardial infarction and/or non-elective revascularisation.

Results A total of 915 of 1753 (52.2%) patients (mean age 56.8 ± 12.0 years; 46.2% male) had a zero CAC score. Of the 751 (82.1%) patients with a zero CAC in whom CTCA was performed, 674 (89.7%) had normal coronary arteries, 63 (8.4%) had non-calcified CAD with < 50% stenosis and 14 (1.9%) had ≥ 50% stenosis in at least one coronary artery. The negative predictive value of a zero CAC for excluding a ≥ 50% CTCA stenosis was 98.1%. Over a median follow-up period of 2.2 years (range 1.0–7.0 years), the absolute annualised rates of MACE were as follows: zero CAC 1.9 per 1000 person-years and non-zero CAC 7.4 per 1000 person-years (HR 3.8, p = 0.009). However, after adjusting for age, gender and cardiovascular risk factors using a multivariable Cox proportional hazards model, there was no statistically significant difference in the risk of MACE between the two patient cohorts (p = 0.19). After adjusting for age, gender and cardiovascular risk factors, the HR for all-cause mortality among the zero CAC cohort vers non-zero CAC was 2.1 (p = 0.27).

Conclusion A zero CAC score in patients undergoing CT scanning for suspected stable angina has a high negative predictive value for the exclusion of obstructive CAD and is associated with a good medium-term prognosis.

  • coronary artery disease
  • chest pain clinic
  • CT scanning
  • risk stratification

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Contributors XW and EPVL contributed equally to the data collection, the statistical analysis and drafted the initial manuscript. JMT, NJHP and NKR contributed to the data collection. HP advised on the statistical analysis. JHFR, JB, MW, JMT and DG planned the study and JHFR is the study guarantor.

  • Funding JHFR is part-supported by the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre, the Higher Education Funding Council for England, the British Heart Foundation, the EPSRC and the Wellcome Trust. EPVL is funded by the Frank Edward Elmore Fund and the Medical Research Council’s Doctoral Training Partnership. JMT is supported by the Wellcome Trust.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The study was a planned clinical service evaluation and was carried out after favourable review by the hospital’s audit board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.